2026 NPPES data Hematology & Oncology Physician NPI 1295829042 M.D.
Verify on CMS →

INAGANTI SHAH, M.D.

Hematology & Oncology Physician in OMAHA, Nebraska. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
955
Medicare Part D claims · 223 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
84%
generic claims · 16% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$204.9
9 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: INAGANTI SHAH, M.D. is a Hematology & Oncology Physician ([object Object]) practicing in OMAHA, Nebraska with a Medicare Part D prescribing footprint of 955 claims across 223 beneficiaries — 16% brand-name prescribing . Industry payments of $204.9 across 9 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: INAGANTI SHAH, M.D. filed 955 Medicare Part D claims in 2023 across OMAHA, Nebraska. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

INAGANTI SHAH, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 2 hospital affiliations — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

INAGANTI SHAH, M.D. at a glance

Quality data not reported

NPI registry status

Active

Issued 10/03/2006

NPI 1295829042

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

955 13% vs specialty avg

2023 prescription claims

Specialty avg: 847

Specialty distribution in Nebraska

How Hematology & Oncology Physician compares to other specialties among Nebraska providers

Nebraska providers

Hematology & Oncology Physician share within Nebraska

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Nebraska

Specialty board-certification context

Estimated specialty board-certified rate — Hematology & Oncology Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Hematology & Oncology Physician ABMS/AOA estimate

Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Hematology & Oncology Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

INAGANTI SHAH, M.D. is a Hematology & Oncology Physician provider practicing in OMAHA, Nebraska, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1295829042. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

INAGANTI SHAH, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 6901 N 72ND ST, OMAHA, NE, 68122, with a listed phone of (402) 572-3535. NPI 1295829042 was issued on 10/03/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what SHAH most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 955 prescription claims written by this provider, covering 223 Medicare beneficiaries and totaling roughly $1.7 million in drug spend, split 16% brand-name and 84% generic by claim count, with an opioid prescribing rate of 5.2%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

6901 N 72ND ST
OMAHA, NE 68122

Provider Details

NPI 1295829042
Specialty Hematology & Oncology Physician
Credentials M.D.
Gender Male
NPI Issued 10/03/2006

Hospital and facility affiliations

Facilities where INAGANTI SHAH, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

ALEGENT CREIGHTON CLINIC
OMAHA, NE
HEMATOLOGY AND ONCOLOGY CONSULTANTS PC
NORFOLK, NE

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for INAGANTI SHAH, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$205

Largest payer

PFIZER INC.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Typical

INAGANTI SHAH, M.D. — brand share 16.0%
Specialty average (est.)

16% brand-name claims vs 84% generic, on 955 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

955
Total Claims
$1.7M
Total Drug Cost
223
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,227
Total Day Supply
30,835
Brand vs Generic
16% brand / 84% generic
Brand Drug Cost
$1.4M
Generic Drug Cost
$317K
Opioid Claims
50 (5.2% rate)
Antibiotic Claims
18

Patient Demographics

Average Patient Age
72.4 years
Avg HCC Risk Score
2.26
Gender Split
61% female / 39% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Dexamethasone
103
Anastrozole
97
Prednisone
61
Abiraterone Acetate
55
Ondansetron Hcl
42
Hydroxyurea
39
Xarelto
Rivaroxaban
29
Imbruvica
Ibrutinib
24
Acyclovir
22
Tamoxifen Citrate
22

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How INAGANTI SHAH, M.D. fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

INAGANTI SHAH, M.D.'s 955 claims are above the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Nebraska

Other clinicians with the same primary specialty enrolled in Nebraska, drawn from the same CMS NPPES roster as SHAH.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is INAGANTI SHAH, M.D.'s specialty?
INAGANTI SHAH, M.D. specializes in Hematology & Oncology Physician and practices in OMAHA, Nebraska. Credentials: M.D..
How much does INAGANTI SHAH, M.D. prescribe under Medicare Part D?
In 2023, INAGANTI SHAH, M.D. wrote 955 Medicare Part D claims totaling $1.7M in drug costs for 223 beneficiaries.
Where is INAGANTI SHAH, M.D. located?
INAGANTI SHAH, M.D. is located at 6901 N 72ND ST, OMAHA, NE, 68122. Phone: (402) 572-3535.
What is INAGANTI SHAH, M.D.'s NPI number?
INAGANTI SHAH, M.D.'s National Provider Identifier (NPI) is 1295829042, issued on 10/03/2006.
Does INAGANTI SHAH, M.D. prescribe more brand-name or generic drugs?
INAGANTI SHAH, M.D.'s prescribing is 16% brand-name and 84% generic drugs by claim count, with $1.4M in brand drug costs.
Does INAGANTI SHAH, M.D. prescribe opioids?
Yes, INAGANTI SHAH, M.D. had 50 opioid claims in 2023 with an opioid prescribing rate of 5.2%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does INAGANTI SHAH, M.D. prescribe most often?
Based on 2023 Medicare Part D data, INAGANTI SHAH, M.D.'s most frequently prescribed drugs include Dexamethasone, Anastrozole, Prednisone. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does INAGANTI SHAH, M.D. accept Medicare?
INAGANTI SHAH, M.D. appears in CMS Medicare data with 955 Part D claims and 223 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify INAGANTI SHAH, M.D.'s credentials?
INAGANTI SHAH, M.D.'s NPI is 1295829042 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology